Incyte (INCY) Leerink Global Healthcare Conference 2026 summary

Strategic focus and business outlook

• Core business excluding Jakafi is projected to reach $3–4 billion in sales over five years, aiming to match Jakafi's size by 2030, with new launches and upcoming approvals for XR and povorcitinib.

• Pipeline investment is concentrated on seven assets in hematology, oncology, and immunology, with 14 clinical studies planned by 2026.

• Business development remains a key lever for supplementing growth and extending the franchise.

Jakafi performance and lifecycle management

• Jakafi maintains mid-single-digit growth through 2028, with XR formulation launching mid-2026 to preserve revenue post-exclusivity.

• Conversion to XR is expected at around 20%, potentially preserving $750 million in annual revenue.

• Pricing strategy for XR aims for parity with IR, focusing on formulary access and stable patient out-of-pocket costs.

• Formulary coverage for XR will take 6–12 months post-launch, with conversion efforts extending through 2027.

Pipeline highlights: INCA33989 and CALR pathway

• INCA33989, a CALR-targeted antibody, shows first-line efficacy in second-line studies for ET and MF, with potential to surpass current standards if phase III replicates phase I results.

• Phase III trials for INCA33989 in ET and MF will begin mid and late 2024, aiming to establish molecular-targeted therapies as standard of care.

• INCA33989 demonstrates disease modification by eradicating mutated cells, improving anemia, and reducing bone marrow fibrosis.

• CALR mutations are present in 25% of ET and 35% of MF patients, with type 1 mutations being most common.

• Dosing strategies in pivotal trials will address differences in affinity for CALR mutation subtypes, with clarity on trial design expected by April.